Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8952W HIGH $7.80
Volume
189.97 K
Value Traded
516.19 K
Short % Float
4.06%
Days to Cover
1.6
-15.85%Week
-33.01%1 Month
+18.97%3 Month
-39.47%6 Month
-99.77%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
24.12 M
EPS (TTM)
-1.29
P/E Ratio
-
Ent. Value
17.59 M
Total Shares
17.48 M
Float Shares
16.37 M
Insiders
6.94%
Institutions
11.77%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CVM Catalyst Timeline
Dated clinical, regulatory and corporate events for Cel-Sci Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cel-Sci Corporation
126Total events
4Upcoming
22Tier-1 (high impact)
2013 to 2026Coverage
Upcoming catalysts 2
TBD
T2Other Regulator Milestone
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 50
●Oral PresentationMultikinePresentation
CEL-SCI presents Phase 3 Multikine biomarker data at World Congress
head and neck cancersource ↗
▲Biomarker DataMultikineClinical Data
Phase 3 Multikine pre-surgical biomarker data showing 73% 5-year survival
head and neck cancersource ↗
▲PublicationMultikinePresentation
Oral Oncology publication of biomarker and survival data from Phase 3 study
head and neck cancersource ↗
▲Partnership / LicenseMultikineCorporate
Partnership with Amarox for Saudi Arabia approval and commercialization
head and neck cancersource ↗
▲Trial InitiationMultikineTrial
Enrollment to commence in 212-patient Confirmatory Registration Study
head and neck cancersource ↗
▲PublicationMultikinePresentation
Publication in Oral Oncology of IT-MATTERS study results
head and neck cancersource ↗
▲PublicationMultikinePresentation
Manuscript accepted for publication in Oral Oncology
head and neck cancersource ↗
◆Trial InitiationMultikineTrial
Launch of FDA Registration-Enabling Phase 3 Confirmatory Study
newly diagnosed head and neck cancersource ↗
▲Trial InitiationMultikineTrial
Enrollment to commence in 212-patient Confirmatory Registration Study
head and neck cancersource ↗
▲Partnership / LicenseCorporate
Strategic agreement signing ceremony with Saudi Amarox at BIO 2026
cancersource ↗
▼Equity OfferingCorporate
Pricing of best-efforts offering of 2,500,000 shares at $1.00 per share
▲Partnership / LicenseMultikineCorporate
Strategic partnership with Amarox for registration, commercialization, and distribution in Saudi Arabia
head and neck cancersource ↗
◆Trial InitiationMultikineTrial
Start enrollment in U.S. FDA confirmatory Registration trial of Multikine in head and neck cancer
head and neck cancersource ↗
▼Equity OfferingCorporate
Pricing of $10 million public offering of 1,111,200 shares at $9.00 per share
▼Equity OfferingCorporate
Pricing of $5.7 million best-efforts offering of 1,500,000 shares at $3.82 per share
▼Equity OfferingCorporate
Pricing of underwritten public offering of 2,000,000 shares at $2.50 per share
▼Equity OfferingCorporate
Raised approximately $28.3 million through sale of common stock in fiscal 2025
▼Equity OfferingCorporate
Pricing of $5 million public offering of common stock and pre-funded warrants
◆Trial InitiationMultikineTrial
Confirmatory trial enrollment expected to begin in Q4 2024
head and neck cancersource ↗
▲Poster PresentationMultikinePresentation
Poster presentation at ESMO 2024 on prognostic significance of diagnostic staging in treatment naïve, resectable locally advanced primary oral cavity squamous cell carcinoma for neoadjuvant Leukocyte Interleukin Injection immunotherapy
locally advanced resectable head and neck cancersource ↗
▲Full ResultsMultikineClinical Data
New analysis of Phase 3 study data: target low risk population (n=79) showed 5-year OS 82.6% vs 47.3%, HR 0.27
locally advanced resectable head and neck cancersource ↗
▼Equity OfferingCorporate
Pricing of $10.8 million best-efforts offering of common stock and pre-funded warrants
▲Full ResultsMultikineClinical Data
Positive bias analysis results for Phase 3 study of Multikine in head and neck cancer
head and neck cancersource ↗
▲Oral PresentationMultikinePresentation
Presentation of head and neck cancer data at IDDST Annual Congress in Budapest
head and neck cancersource ↗
◆IND SubmissionMultikineIND
Plan to submit proposed study protocol to FDA in Q1 2024
advanced primary head and neck cancersource ↗
◆Other Regulator MilestoneMultikineEx-US Regulatory
Plan to present new data to Canadian regulators
head and neck cancersource ↗
◆Oral PresentationMultikinePresentation
Plan to present new data to FDA in next quarter
head and neck cancersource ↗
●Timing GuidanceMultikinePresentation
Planned NOCC application filing with Health Canada later this year/early next year
newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN)source ↗
◆FDA ApprovalMultikineFDA Decision
Possible commercialization in Canada as early as 2024 if Health Canada clears submission
newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN)source ↗
▲Oral PresentationMultikinePresentation
ESMO 2023 poster presentation of 5-year survival data in target population
head and neck cancersource ↗
▲Full ResultsMultikineClinical Data
5-year overall survival data in target population: 73% vs 45%, HR 0.35, p=0.0015
head and neck cancersource ↗
▲Oral PresentationMultikinePresentation
New data on Multikine efficacy presented at ESMO conference
head and neck cancersource ↗
●Other Regulator MilestoneMultikineEx-US Regulatory
Presented new data to regulators in Europe and UK
head and neck cancersource ↗
●Other Regulator MilestoneMultikineEx-US Regulatory
Pre-application regulatory filings submitted in UK and Europe
head and neck cancersource ↗
▼Equity OfferingCorporate
Closing of public offering of 2,500,000 shares at $2.00 per share for gross proceeds of $5,000,000
▼Equity OfferingCorporate
Pricing of underwritten public offering of 2,500,000 shares at $2.00 per share for gross proceeds of $5,000,000
▲FDA Feedback ReceivedMultikineFDA Meeting
Positive FDA meeting regarding Multikine approval path for head and neck cancer
newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN)source ↗
Past FDA Catalysts and PDUFA Decisions
How CVM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-26 | Multikine (Leukocyte Interleukin, Injection) | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 99%
Micro Cap(rank 650 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every CVM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Multikine Orphan | head and neck cancer | Phase 3 | 2026-10-26 | 73% five-year survivalRead More | CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year SurvivalRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| KERSTEN GEERT RDirector, Officer (Chief Executive Officer) | Buy | 100,000 316,142 held | $1.38 | 08/25/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CVM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TRI LOCUM PARTNERS LP | 0 % | 50.00 K | 11.21 K |
CVM Institutional Ownership Trends
CVM Short Interest
Shares sold short, counted twice a month.
4.06%
Short % of Float
of tradable shares sold short
663.8K
Shares Sold Short
+12.1% vs prior count
1.6 Low
Days to Cover
trading days of normal volume to buy every short share back
412.8K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CVM ranks across every disease it competes in
Competitive Position is a premium feature
See how CVM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCVM News
CVMCEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival
CEL-SCI presented new Phase 3 data for Multikine at the World Congress. The study highlighted that pre-surgical biomarkers can identify head and neck cancer patients who achieve a 73% five-year survival rate. This data may enhance patient selection for treatment.
Read more →CVMCEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
CEL-SCI has been invited to present a keynote address on its product Multikine at the 6th World Congress on Otology, Rhinology, and Laryngology. This invitation underscores the importance of Multikine in the field. The congress provides a platform for sharing advancements in otology, rhinology, and laryngology.
Read more →CVMCEL-SCI Reports Fiscal Third Quarter 2026 Results
CEL-SCI has announced its financial results for the third quarter of fiscal 2026, which ended on June 30. The report includes significant updates on corporate and clinical developments related to Multikine. This reflects the company's ongoing efforts in advancing its product pipeline.
Read more →CVM▲ +8.8%on this news· ran to +38% by day 3
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study
A recent study published in the peer-reviewed journal Oral Oncology highlights the efficacy of CEL-SCI's Multikine in supporting its biomarker strategy. The findings suggest a potential overall survival benefit for patients, particularly ahead of the upcoming confirmatory registration study for head and neck cancer.
Read more →CVM▲ +7%on this news· ran to +19% by day 3shared move
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
CEL-SCI's Multikine Phase 3 data has been accepted for publication in a leading oncology journal. This study demonstrates an overall survival benefit for patients with head and neck cancer, particularly those from underserved populations. The publication marks a significant milestone for CEL-SCI in showcasing the effectiveness of its treatment.
Read more →CVM▼ -11.6%on this news
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
CEL-SCI is set to initiate a Phase 3 confirmatory study for Multikine, aimed at obtaining FDA registration. This study focuses on newly diagnosed patients with head and neck cancer, marking a significant step towards bringing this treatment to market. The initiative reflects CEL-SCI's commitment to addressing critical needs in oncology.
Read more →CVMCEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care
CEL-SCI and Saudi Amarox recently held a strategic agreement signing ceremony at BIO 2026. This event marks a significant step in enhancing cooperation between the U.S. and Saudi Arabia in the field of cancer care. The collaboration aims to leverage resources and expertise to improve cancer treatment options.
Read more →CVM▼ -6.5%on this news
CEL-SCI CORPORATION ANNOUNCES PRICING OF OFFERING
CEL-SCI Corporation announced the pricing of a best-efforts offering of 2,500,000 shares of common stock at $1.00 per share, aiming to raise $2.5 million. The funds will be used for the development of their cancer immunotherapy, Multikine, and for general corporate purposes. The offering is set to close on June 16, 2026, pending customary closing conditions. Important to note, the company has emphasized the presence of risks associated with their forward-looking statements regarding regulatory approvals and the clinical efficacy of their product.
Read more →CVM▼ -15.6%on this news
CEL-SCI Corporation Announces Pricing of Public Offering - May 11, 2026
CEL-SCI Corporation has announced a public offering of 6,000,000 shares priced at $1.20 each, aiming to raise approximately $7.2 million. The funds will be allocated towards the development of their cancer immunotherapy, Multikine, and for general corporate purposes. The offering is set to close on May 13, 2026, pending customary conditions.
Read more →CVM▼ -17.1%on this news· ran to -30% by day 1shared move
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia
CEL-SCI Corporation has signed a strategic partnership with Amarox for the registration and commercialization of its immunotherapy Multikine in Saudi Arabia. The agreement includes a 50/50 revenue sharing model and Amarox will act as the local regulatory representative with the Saudi Food and Drug Authority. This partnership aims to expedite Multikine's approval as a treatment for head and neck cancer, addressing significant unmet medical needs in the region, with potential expansion to other Gulf Cooperation Council countries.
Read more →CVM▼ -17.1%on this news· ran to -30% by day 1shared move
CEL-SCI Corporation Announces Pricing of Public Offering
CEL-SCI Corporation announced the pricing of a public offering of 6,000,000 shares of its common stock at $1.20 per share, aiming to raise approximately $7.2 million. The proceeds are designated for the development of Multikine, a cancer immunotherapy, as well as working capital and general corporate purposes. The offering is expected to close on May 13, 2026, pending standard closing conditions. The company has previously received Orphan Drug designation from the FDA for Multikine, which targets tumors in patients diagnosed with squamous cell carcinoma of the head and neck.
Read more →CVM▲ +8.4%on this news
CEL-SCI Reports Fiscal First Quarter 2026 Results
CEL-SCI Corporation reported its fiscal first quarter 2026 results, highlighting key milestones including the upcoming enrollment in a U.S. FDA confirmatory trial for Multikine in head and neck cancer. The company aims to submit data for commercialization in the U.S. and other global markets. Financial results showed a reduced net loss compared to the previous year, despite ongoing expenses.
Read more →CVM▲ +10.2%on this news
CEL-SCI Reports Fiscal 2025 Results
CEL-SCI Corporation reported its fiscal 2025 results, highlighting regulatory advancements for its cancer therapy, Multikine, including a Confirmatory Registration trial approved by the FDA. The trial aims to validate previous Phase 3 study results, showing improved survival rates. The company experienced a decrease in net loss but raised concerns regarding its financial sustainability.
Read more →CVM▲ +15.4%on this news
CEL-SCI ANNOUNCES PRICING OF $10 MILLION PUBLIC OFFERING
CEL-SCI Corporation announced the pricing of a $10 million public offering, selling 1,111,200 shares of common stock at $9.00 each. The offering is set to close on August 29, 2025, pending customary closing conditions. Proceeds will support the development of Multikine, an investigational cancer immunotherapy, along with general corporate purposes and working capital. The offering follows SEC regulations and will strengthen CEL-SCI's financial position in advancing their clinical efforts.
Read more →CVM▼ -7.6%on this news
CEL-SCI ANNOUNCES PRICING OF $5.7 MILLION OFFERING
CEL-SCI Corporation has announced a $5.7 million offering of 1,500,000 shares of its common stock priced at $3.82 each. The proceeds are designated for the continued development of their cancer immunotherapy, Multikine, along with general corporate purposes. The offering is expected to close on July 14, 2025, subject to customary conditions. The company emphasizes the importance of funding its immunotherapy development amidst potential regulatory challenges.
Read more →CVM▼ -11.7%on this news· ran to -52% by day 1
CEL-SCI ANNOUNCES PRICING OF PUBLIC OFFERING
CEL-SCI Corporation has announced the pricing of an underwritten public offering of 2,000,000 shares at $2.50 per share, aiming to raise approximately $5 million. The funds will be used for the ongoing development of Multikine and for general corporate purposes. The offering is expected to close on May 23, 2025, subject to customary conditions. The firm has filed the necessary registration with the SEC and plans to continue advancing its cancer immunotherapy pipeline.
Read more →CVM▼ -6.5%on this news
CEL-SCI ANNOUNCES PRICING OF $2.5 MILLION OFFERING
CEL-SCI Corporation announced the pricing of a $2.5 million offering of 16 million shares aimed at funding the development of its cancer immunotherapy, Multikine. The offering is expected to close soon, contingent on customary conditions. Multikine has shown promise, receiving FDA Orphan Drug designation for treating head and neck cancer. The company emphasizes the importance of supporting patient immune systems during treatment.
Read more →CVM▼ -32.3%on this news
CEL-SCI ANNOUNCES PRICING OF $5 MILLION PUBLIC OFFERING
CEL-SCI Corporation has announced a $5 million public offering of 16,130,000 shares of common stock, priced at $0.31 per share. The gross proceeds will be directed towards the further development of Multikine, an investigational cancer immunotherapy, and general corporate purposes. The offering is set to close on December 31, 2024, pending the satisfaction of customary closing conditions. CEL-SCI's Multikine has received Orphan Drug designation and is preparing for a confirmatory study involving 212 patients with specific cancer characteristics.
Read more →CVM▲ +5.2%on this news
CEL-SCI's Multikine Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and
CEL-SCI Corporation reported that its Multikine treatment has increased the 5-year survival rate for locally advanced resectable head and neck cancer patients to 82.6%. This data, presented at ESMO 2024, shows significant survival benefits, particularly for patients deemed at low risk for recurrence who received only radiotherapy after surgery. The FDA has approved a confirmatory Registration Study, which will focus on a well-defined patient population to optimize treatment outcomes further. These findings highlight the potential of Multikine as a key immunotherapy option in this patient demographic.
Read more →CVM▲ +8.3%on this news
CEL-SCI'S PHASE 3 POPULATION ANALYSIS FOR UPCOMING CONFIRMATORY REGISTRATION STUDY IN HEAD & NECK CANCER DEMONSTRATES WELL BALANCED PATIENT POPULATION, CONFIDENCE IN CLINICAL RESULTS
CEL-SCI Corporation announced positive results from a bias analysis of its Phase 3 study for Multikine in head and neck cancer, showing well-balanced patient demographics. The analysis concluded that there was no bias affecting the results, reinforcing confidence in the treatment’s efficacy. The upcoming confirmatory registration study, approved by the FDA, aims to enroll 212 patients to further validate Multikine's promising survival rates versus control. Notably, the treatment demonstrated a 73% five-year survival rate compared to 45% for the control group.
Read more →About Cel-Sci Corporation
Headquarters8229 BOONE BLVD ., VIENNA, VA, 22182
BIOPHARMAWATCH ELITE PLUS
Trade the next CVM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime